NCT06398639View on ClinicalTrials.gov

Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

NARecruitingINTERVENTIONAL
Enrollment

1,500

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2030

Conditions
Prostate CancerPolygenic Risk Score
Interventions
OTHER

Polygenic Risk Score (PRS)

"Participants will be put into PRS cohorts based on their genetic data.~All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score."

Trial Locations (4)

20060

NOT_YET_RECRUITING

Howard University Hospital, Washington D.C.

20814

NOT_YET_RECRUITING

National Cancer Institute, Bethesda

NOT_YET_RECRUITING

Walter Reed National Military Medical Center, Bethesda

02155

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Adam S. Kibel, MD

OTHER